Effects of increasing doses of samarium-153-ethylenediaminetetramethylene phosphonate on axial and appendicular skeletal growth in juvenile rabbits

Nuclear Medicine and Biology

Volumn 35, Issue 2, 2008, Pages 219-225

  Essman, Stephanie C ^a   Lewis, Michael R ^a,b,c,d   Fox, Derek B ^a  

^a UNIVERSITY OF MISSOURI   (United States)

^b University of Missouri   (United States)

^c UNIVERSITY OF MISSOURI   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Bone growth; Osteosarcoma; Physeal cartilage; Samarium 153 ethylenediaminetetramethylene phosphonate

Indexed keywords

ETHYLENEDIAMINETETRAMETHYLENE PHOSPHONATE SM 153; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE GROWTH; BONE SCINTISCANNING; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG MEGADOSE; FEMALE; IONIZING RADIATION; JUVENILE; LOW DRUG DOSE; NONHUMAN; RABBIT; STATISTICAL ANALYSIS;

ANIMALS; BONE AND BONES; BONE DEVELOPMENT; DOSE-RESPONSE RELATIONSHIP, RADIATION; FEMALE; GROWTH PLATE; PHOSPHONIC ACIDS; RABBITS; RADIOISOTOPES; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; SAMARIUM;

EID: 38849121284     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2007.11.005     Document Type: Article

References (34)

1. Eifel P.J., Donaldson S.S., and Thomas P.F. Response of growing bone to irradiation: a proposed late effects scoring system. Int J Radiat Oncol Biol Phys 31 (1995) 1301-1307
2. Melanotte P.L., and Follis R.H. Early effects of x-irradiation on cartilage and bone. Am J Pathol 39 (1961) 1-7
3. Rutherford H., and Dodd G.D. Complications of radiation therapy: growing bone. Semin Roentgenol 9 (1974) 15-27
4. Probert J.C., and Parker B.R. The effects of radiation therapy on bone growth. Radiology 114 (1975) 155-162
5. Parker R.G., and Berry H.C. Late effects of therapeutic irradiation on the skeleton and bone marrow. Cancer 37 (1976) 1162-1171
6. Gonzalez D.G., and Breur K. Clinical data from irradiated growing long bones in children. Int J Radiat Oncol Biol Phys 9 (1983) 841-846
7. Ben-Josef E., and Porter A.T. Radioisotopes in the treatment of bone metastases. Ann Med 29 (1997) 31-35
8. Serafini A.N. Current status of systemic intravenous radiopharmaceuticals for the treatment of painful metastatic bone disease. Int J Radiat Oncol Biol Phys 30 (1994) 1187-1194
9. Campa J.A., and Payne R. The management of intractable bone pain: a clinician's perspective. Semin Nucl Med 22 (1992) 3-10
10. Serafini A.N. Systemic metabolic radiotherapy with samarium-153-EDTMP for the treatment of painful bone metastasis. Q J Nucl Med 45 (2001) 91-99
11. Janjan N. Bone metastasis: approaches to management. Semin Oncol 28 (2001) 28-34
12. Diener K.M. Bisphosphonates for controlling pain from metastatic bone disease. Am J Health Syst Pharm 53 (1996) 1917-1927
13. Goeckeler W.F., Edwards B., Volkert W.A., Holmes R.A., Simon J., and Wilson D. Skeletal localization of samarium-153 chelates: potential therapeutic bone agents. J Nucl Med 28 (1987) 495-504
14. Lattimer J.C., Corwin L.A., Stapleton J., et al. Clinical and clinicopathologic response of canine bone tumor patients to treatment with samarium-153-EDTMP. J Nucl Med 31 (1990) 1316-1325
15. 153Sm-EDTMP. J Pediatr Oncol Nurs 15 (1998) 95-97
16. Gaitan-Yanguas M. A study of the response of osteogenic sarcoma and adjacent normal tissue to radiation. Int J Radiat Oncol Biol Phys 7 (1981) 593-595
17. 153Sm-EDTMP. Clin Cancer Res 5 (1999) 3148s-3152s
18. Franzius C., Bielack S., Vollet B., Jurgens H., and Schober O. High-activity samarium-153 EDTMP therapy in unresectable osteosarcoma. Nuklearmedizin 38 (1999) 337-340
19. Franzius C., Bielack S., Flege S., Eckardt J., Sciuk J., and Schober O. High-activity samarium-153-EDTMP therapy followed by autologous peripheral blood stem cell support in unresectable osteosarcoma. Nuklearmedizin 40 (2001) 215-220
20. Anderson P.M., Wiseman G.A., Dispenzieri A., et al. High dose samarium-153 ethylene diamine tetramethylene phosphonate: low toxicity of skeletal irradiation in patients with osteosarcoma and bone metastases. J Clin Oncol 20 (2001) 189-196
21. Anderson P.M., et al. Gemcitabine radiosensitization after high dose samarium for osteoblastic osteosarcoma. Clin Cancer Res 11 (2005) 6895-6900
22. Anderson P.M. Samarium for osteoblastic bone metastasis and osteosarcoma. Expert Opin Pharmacother 7 (2006) 1475-1486
23. 153Sm]EDTMP: a potential therapy for bone cancer pain. Semin Nucl Med 22 (1992) 41-45
24. Turner J.H., Martindale A.A., Sorby P., et al. Samarium-153 EDTMP therapy of disseminated skeletal metastasis. Eur J Nucl Med 15 (1989) 784-795
25. Serafini A.N., Houston S.J., Resche I., et al. Palliation of pain associated with metastatic bone cancer using samarium-153 lexidronam: a double-blind placebo-controlled clinical trial. J Clin Oncol 16 (1998) 1574-1581
26. Bayouth J.E., Macey D.J., Kasi L.P., and Fossella F.V. Dosimetry and toxicity of samarium-153-EDTMP administered for bone pain due to skeletal metastases. J Nucl Med 35 (1994) 63-69
27. Probert J.C., and Parker B.R. The effects of radiation therapy on bone growth. Radiology 114 (1975) 155-162
28. Frantz C.H. Extreme retardation of epiphyseal growth from roentgen irradiation. Radiology 55 (1950) 720-724
29. Shapiro F. Epiphyseal and physeal cartilage vascularization: a light microscopic and tritiated thymidine autoradiographic study of cartilage canals in newborn and young postnatal rabbit bone. Anat Rec 252 (1998) 140-148
30. Gonzalez D.G., and Van Dijk D.P. Experimental studies on the response of growing bones to x ray and neutron irradiation. Int J Radiat Oncol Biol Phys 9 (1983) 671-677
31. Essman S.C., Lewis M.R., and Miller W.H. Intra-organ biodistribution and dosimetry of 153Sm-EDTMP in the juvenile rabbit tibia: implications for targeted radiotherapy of osteosarcoma. J Nucl Med 46 (2005) 2076-2082
32. 153Sm-EDTMP on physeal and articular cartilage in juvenile rabbits. J Nucl Med 44 (2003) 1510-1515
33. Farhanghi M., Holmes R.A., Volkert W.A., Logan K.W., and Singh A. Samarium-153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment for metastatic bone cancer. J Nucl Med 33 (1992) 1451-1458
34. Collins C., Eary J.F., Donaldson G., et al. Samarium-153-EDTMP in bone metastases of hormone refractory prostate carcinoma: a phase I/II trial. J Nucl Med 34 (1993) 1839-1844